A new investigational drug called zabopegdutide may treat metabolic liver disease directly, not just through weight loss. In a Phase 2 trial published in The Lancet Gastroenterology & Hepatology, patients with MASH saw significant reductions in liver fat and liver stiffness within just 12 weeks — even those who had lost less than 5% of their body weight. Nearly 75% of patients reduced liver fat by more than half, and almost half reached normal liver fat levels. These early improvements appear to foreshadow stronger 48-week results showing reduced scarring and disease resolution confirmed by biopsy. The findings suggest this once-weekly therapy may offer a dual mechanism: direct liver action plus additional benefits from weight reduction.
